December 03, 2018
1 min read

MRCP+ imaging quantitatively characterizes hepatobiliary diseases

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Perspectum Diagnostics released information on its MRCP+ noninvasive imaging technology at The Liver Meeting 2018, according to a press release.

MRCP+ was designed to enhance and quantitatively characterize existing magnetic resonance cholangiopancreatography for the evaluation of hepatobiliary diseases, such as primary sclerosing cholangitis.

According to data from the release, the technology enhances data from conventional MRCP without needing to inject contrast agent, enabling 3D visualization and measurement of bile duct widths and automatic detection of regions of variation of duct widths.

In one study presented at the meeting, researchers assessed images from patients with primary biliary cholangitis and PSC. Further assessment with MRCP+ demonstrated that a multi-scale image analysis method both enhanced and quantified biliary tubular structures. MRCP+ provided measures that could objectively differentiate patients with PSC with an AUROC of 0.94.

Another study presented showed a good correlation between MRCP+ measurement and the biomarker Matrix Metalloproteinase 7 (MMP7), which correlated with the presence of periductal sclerosis (P < .001) and lymphocytic cholangitis (P = .04).


Mavar M, et al. Abstract 1952. Presented at: The Liver Meeting 2018; Nov. 9-13, 2018; San Francisco.

Lam S, et al. Abstract 0183. Presented at: The Liver Meeting 2018; Nov. 9-13, 2018; San Francisco.